conducted a neoadjuvant study in which 181 Japanese patients with stage II/IIIA HER2-negative breast cancer were randomly assigned to four 3-week cycles of carboplatin (AUC of 5, day 1) in combination with weekly paclitaxel (80 mg/m2, days 1, 8, 15) followed by four 3-week cycles of cyclophosphamide, epirubicin, and 5-fluorouracil (CEF) or weekly paclitaxel followed by four 3-week cycles of CEF. Here, ERBB2 is linked to breast carcinoma.